Design, Development and Evaluation of Liposomal Formulations of Fulvestrant for Targeted Drug Delivery Breast Cancer

Mainaim of current research was to determine feasibility of developing, designing, and testing liposomal formulations loaded with Fulvestrant for purpose of targeted drug transfer in management of breast cancer. With an impressive encapsulation effectiveness of 85%, they were made utilizing the thin-film hydration approach solvent evaporation followed high pressure homogenization technique for particle size reduction..The physicochemical characterization, these liposomess were seen to be in the dimension of <150-200nm with low polydispersity index (<0.3), -25 mV of the zeta potential, and indicated stability and will also be best for an in vivo application. Ex-vivo diffusion will reveal high numbers of drugs being released as compared to free Fulvestrant and further made the release sustained over 48 hours. Cytotoxic evaluation of MCF-7 breast cancer cells was exhibited that for fulvestrant-loaded liposomes at 5 μM, there was a 50% reduction of cell viability-which is an extremely significant increase compared with free drug (30% reduction). Pharmacokinetic study did exhibit an improvement in bioavailability due to increased circulation time, fetching changes in drug accumulation into tumor tissues through enhancement of permeability and retention phenomenon. It means nearly all formulations have comparatively mild hemolytic activity less than 5%, thereby exhibiting probable safety. This study brings into light a very feasible total approach of Fulvestrant-loaded liposomes for a prolonged tumor targeting by showing diminished exposures to such drug as compared to conventional injectable therapies offering therapeutic potential enhancement with lesser side effects. The overall findings would provide good ground to conduct further in vivo testing of these formulations for clinical applicability.